Jaguar Health Inc (NASDAQ:JAGX) dropped 7.4% during mid-day trading on Tuesday . The stock traded as low as $0.25 and last traded at $0.25. Approximately 615,605 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 703,093 shares. The stock had previously closed at $0.27.
Separately, ValuEngine upgraded shares of Jaguar Health from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.31 and a current ratio of 0.46.
Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Monday, November 19th. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter. Jaguar Health had a negative return on equity of 259.67% and a negative net margin of 908.28%. The company had revenue of $1.13 million during the quarter.
ILLEGAL ACTIVITY WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2019/01/22/jaguar-health-jagx-stock-price-down-7-4.html.
About Jaguar Health (NASDAQ:JAGX)
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.